N-Acetyltryptophan sodium salt | 62307-74-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-Acetyltryptophan sodium salt
• 英文别名: sodium-N-acetyl-DL-tryptophanate；sodium acetyltryptophanate；sodium;N-[1-carboxy-2-(1H-indol-3-yl)ethyl]ethanimidate
• CAS: 62307-74-8
• 化学式: C₁₃H₁₃N₂O₃*Na
• 分子量: 268.248
• InChiKey: UQSHZBSQKMVQBS-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -3.03
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  85
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温下储存于惰性气体中

反应信息

• 作为反应物：
  描述：

  N-Acetyltryptophan sodium salt 、 [(2S,8S)-2-(naphthalene-2-carbonyloxymethyl)-1,2,3,4,6,7,8,9-octahydropyrimido[1,2-a]pyrimidin-5-ium-8-yl]methyl naphthalene-2-carboxylate;chloride 以 氘代氯仿 、 氘代甲醇 为溶剂， 生成 ((2S,8S)-1,3,4,6,7,8-hexahydro-2H-pyrimido[1,2-a]pyrimidine-2,8-diyl)bis(methylene) bis(2-naphthoate) acetyl-D-tryptophanate 、
  参考文献：
  名称：

  Chiral recognition of aromatic carboxylate anions by an optically active abiotic receptor containing a rigid guanidinium binding subunit

  摘要：

  DOI：

  10.1021/ja00195a071

文献信息

• [EN] COMPOSITIONS AND METHODS FOR TREATMENT OF PLATINUM-BASED CHEMOTHERAPEUTIC RESISTANT TUMORS<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT DE TUMEURS RÉSISTANT AUX AGENTS CHIMIOTHÉRAPEUTIQUES À BASE DE PLATINE
  申请人：UNIV GEORGE WASHINGTON

  公开号：WO2021178663A1

  公开（公告）日：2021-09-10

  Embodiments of the instant disclosure relate to novel methods and compositions for treating tumors resistant to platinum-based chemotherapy. In certain embodiments, methods of treating tumors herein can include administering an effective amount of at least one ursolic acid derivative. In certain embodiments, methods of treating tumors herein can include administering an effective amount of at least one ursolic acid derivative in combination with at least one platinum-based chemotherapeutic separately or in a combination therapy. In some embodiments, methods of treating tumors disclosed herein can include screening and/or selecting a subject suitable for treatment on the basis of SENP1 tumor expression. In other embodiments, methods of treating tumors can include administering a composition disclosed herein to a subject, the composition having a combination of at least one ursolic acid derivative and at least one platinum-based chemotherapeutic.

  本公开的实施例涉及用于治疗对铂类化疗药物具有抗药性的肿瘤的新方法和组合物。在某些实施例中，治疗此处肿瘤的方法可以包括给予至少一种熊果酸衍生物的有效量。在某些实施例中，治疗此处肿瘤的方法可以包括给予至少一种熊果酸衍生物的有效量，单独或与至少一种铂类化疗药物联合治疗。在一些实施例中，治疗此处肿瘤的方法可以包括根据SENP1肿瘤表达筛选和/或选择适合治疗的受试者。在其他实施例中，治疗肿瘤的方法可以包括将本文披露的组合物给予受试者，该组合物包含至少一种熊果酸衍生物和至少一种铂类化疗药物。
• [EN] PHARMACEUTICAL COMPOSITIONS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF<br/>[FR] COMPOSITIONS PHARMACEUTIQUES DE MODULATEURS SÉLECTIFS DES RÉCEPTEURS DES ANDROGÈNES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：GTX INC

  公开号：WO2013067170A1

  公开（公告）日：2013-05-10

  This invention provides a pharmaceutical composition comprising Compound I-V, including inter alia solid dosage forms of powder-filled capsule formulations, liquid-filled softgel capsules (softgels), tablets, and sustained release dosage forms, and uses thereof in treating a variety of diseases or conditions in a subject, for example, treating a muscle wasting disease and/or disorder, a bone related disease and/or disorder, metabolic syndrome, diabetes and associated diseases, and others.

  这项发明提供了一种包含化合物I-V的药物组合物，包括固体剂型的填粉胶囊制剂、液体填充软胶囊（软胶囊）、片剂和缓释剂型，以及在治疗受试者中各种疾病或症状中的用途，例如治疗肌肉消耗疾病和/或紊乱、骨相关疾病和/或紊乱、代谢综合征、糖尿病及相关疾病等。
• Novel drug delivery system
  申请人：——

  公开号：US20040110678A1

  公开（公告）日：2004-06-10

  An exogenous pharmaceutical preparation in which a lipid tagged bioactive material is combined with albumin is disclosed. The albumin has a low proportion of lipidic/fatty acid groups (a molar ratio of fatty acid groups to albumin of less than 0.7) and is preferably fatty acid free. The albumin may be naturally extracted such as Human Serum Albumin or recombinantly produced. A range of bioactive substances, such as peptides, proteins or vaccines may be tagged and combined with albumin for human, veterinary or agricultural use. Several antimicrobial peptides are disclosed. Binding to the albumin mediates the biostability of the tagged bioactive material. Due to this stabilization, the antimicrobial activity of a model lipopeptide is enhanced when combined with substantially fatty acid free-albumin. When bound to albumin, therefore, the model lipopeptide exerts an antimicrobial effect at a lower concentration than the model lipopeptide alone.

  本发明揭示了一种外源性制药制剂，其中脂质标记的生物活性物质与白蛋白结合。白蛋白具有低比例的脂质/脂肪酸基团（脂肪酸基团与白蛋白的摩尔比小于0.7），最好是无脂肪酸的。白蛋白可以是天然提取的，例如人血清白蛋白或重组生产的。一系列生物活性物质，例如肽，蛋白质或疫苗，可以被标记并与白蛋白结合，用于人类，兽医或农业用途。揭示了几种抗微生物肽。与白蛋白结合介导了标记的生物活性物质的生物稳定性。由于这种稳定作用，当与基本无脂肪酸的白蛋白结合时，模型脂肽的抗微生物活性得到增强。因此，当结合到白蛋白时，模型脂肽在比模型脂肽单独使用更低的浓度下产生抗微生物效果。
• Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
  申请人：Pipkin D. James

  公开号：US20070020298A1

  公开（公告）日：2007-01-25

  An inhalable formulation containing SAE-γ-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-γ-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus. The formulation can include one or more additional therapeutic agents for use in combination with the corticosteroid. SAE-γ-CD is especially useful for solubilizing esterified corticosteroids.

  提供了一种含有SAE-γ-CD和皮质类固醇的可吸入制剂。该制剂适用于通过任何已知的雾化器雾化给予受试者。该制剂可以包含在套装中。该制剂以水溶液形式给予，但可以作为干粉、即用溶液或浓缩组合物储存。该制剂用于改进的雾化系统，通过吸入给予皮质类固醇。制剂中存在的SAE-γ-CD显著增强了布地奈德的化学稳定性。提供了一种通过吸入给予制剂的方法。该制剂也可以通过传统的鼻腔给药装置给予。该制剂可以包含一个或多个额外的治疗剂，用于与皮质类固醇联合使用。SAE-γ-CD特别适用于溶解酯化皮质类固醇。
• Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
  申请人：Pipkin D. James

  公开号：US20070020299A1

  公开（公告）日：2007-01-25

  An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.

  提供一种含有SAE-CD和类固醇的可吸入制剂。该制剂适用于通过任何已知的雾化器对受试者进行雾化给药。该制剂可以包含在套装中。该制剂以水溶液形式给药，但可以作为干粉、即用溶液或浓缩组合物储存。该制剂用于改进的雾化系统，通过吸入给予类固醇。制剂中的SAE-CD显著增强了布地奈德的化学稳定性。提供了一种通过吸入给药该制剂的方法。该制剂也可以通过常规的鼻腔给药器给药。